See Phase 2 beta-cyclodextrin entry. EU restrictions. Cholesterol depletion at high doses.
Seven-glucose ring cyclodextrin. See Phase 2 and Phase 3 excipients entries. EU E459 with specific maximum levels.
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
| Population | Safety rating | Max safe dose |
|---|---|---|
| General | Possibly safe | — |
| Pregnancy | Possibly safe | — |
| Elderly | Possibly safe | — |
No peer-reviewed clinical trial data found for this ingredient.
Data by supplement.ge — Public Health Institute of Georgia (PHIG)